Jeroen Hoozemans, VU University Medical Center, The Netherlands
Jason Huse, University of Texas MD Anderson Cancer Center, USA
Aims and scope
Acta Neuropathologica Communications (ANC) focuses on the pathogenesis of neurological disease using experimental or human tissues, molecular, cellular, biological and morphological techniques
EUROTAU Series: Reflections on the Status Quo
EUROTAU is an innovative, collaborative research initiative established to tackle unanswered research questions and the mounting challenges posed by Tauopathies. EUROTAU provides a forum for promoting ambitious, innovative, multi-national and multi-disciplinary collaborative research projects, that: i) combine experimental approaches from fundamental, pre-clinical and/or clinical with computational approaches; ii) perform network analyses in different Tauopathies to elucidate the underlying mechanisms that are common as well as those that are different between them, and iii) will add value to existing research by analyzing diseases across traditional clinical boundaries, thereby gaining deeper understanding of the patho-physiological mechanisms of these disorders.
Jadhav et al. explore the current avenues of research regarding competing therapeutic strategies in the treatment of tau neurodegeneration, a key factor in the development of Alzheimer's Disease.
Why publish with ANC?
- No major revisions: only minor revisions are requested that can be performed (and have to be performed) within 3 weeks
- Fast, thorough peer review: group of editors selected on the basis of their insightful, dedicated and prompt service
- Rapid publication: publication within 2 months of submission
- Inclusion in all major indexing services, such as PubMed, MEDLINE and Web of Science
- Open access: enabling it to be read by a much larger set of readers, increasing its visibility
- Competitive APC: flat article-processing charge, with no page limits, color figure charges or submission fees
From the Editors-in-Chief
"The unique combination of human neuropathology with relevant experimental models is essential for understanding the pathogenesis of neurological diseases. Acta Neuropathologica Communications provides a platform for studies that centrally involve human neuropathology and bring new insight in disease mechanisms of neurological diseases using relevant experimental models. We welcome high quality papers that do not require major revisions, resulting in short turn-around times and fast publication. We hope you enjoy Acta Neuropathologica Communications and are looking forward to receive your submissions."
Jeroen Hoozemans, co-Editor-in-Chief, ANC
"As an original member of the ANC editorial board, it has been a pleasure to witness the growth and maturation of this journal first hand. ANC now occupies a well-defined niche for the rapid publication of high-quality work advancing the broad spectrum of neuropathology and its allied sciences. I look forward to receiving and evaluating your compelling manuscripts in the months and years ahead."
Jason T. Huse, co-Editor-in-Chief, ANC
Annual Journal Metrics
22 days to first decision for reviewed manuscripts only
9 days to first decision for all manuscripts
16 days from submission to acceptance
16 days from acceptance to publication
885 altmetric mentions